Search clinical trials for: Plain H1N1 vaccine

Total 8954 results

University Hospitals, Leicester
Public Health England; Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults

Influenza

United Kingdom
Instituto Nacional de Salud Publica, Mexico
Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.

Withdrawn

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Influenza

Mexico
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

H1N1 Influenza Virus

United States
Chiltern Pesquisa Clinica Ltda

Completed

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

H1N1 Influenza Virus | Invasive Solid Tumors

Brazil
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
French National Agency for Research on AIDS and...
GlaxoSmithKline

Completed

Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

HIV Infections

France
Jiangsu Province Centers for Disease Control and...
Hualan Biological Bacterin Co. Ltd.

Completed

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older

Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae Infections

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
Shanghai Institute Of Biological Products

Completed

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Influenza

China
Hopital du Sacre-Coeur de Montreal
GlaxoSmithKline

Completed

Risk of Narcolepsy Associated With Administration of H1N1 Vaccine

Narcolepsy

Canada
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial With Influenza A/H1N1 Vaccines

Influenza

China
University of Rochester

Completed

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Influenza

United States
University of Oxford

Completed

Swine Flu (Novel Influenza A H1N1) Vaccine Study

Influenza

United Kingdom
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Institut... and other collaborators

Completed

Efficacy Safety Study of Flu Vaccine in Immunodepression Patients (MICIVAX)

Inflammatory Bowel Disease (IBD)

France
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Sinovac Biotech Co., Ltd

Completed

Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 + TIV - Adults and Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Chinese Academy of Sciences
Jiangsu Province Centers for Disease Control and Prevention; Hualan Biological...

Unknown

Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Human Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
University of Rochester

Completed

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Influenza

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Vaxart

Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Norovirus Gastroenteritis

United States
National Institute of Allergy and Infectious Diseases...

Completed

H1N1 Vaccine in Pregnant Women

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Influenza

United States
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Sinovac Biotech Co., Ltd

Completed

Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Influenza

China
Sahlgrenska University Hospital, Sweden

Completed

Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients

Organ Transplantation

Sweden
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Mahidol University

Completed

Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais

Healthy

Thailand
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
Oswaldo Cruz Foundation
Ministry of Health, Brazil

Completed

Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (VIP-H1N1)

HIV Infection

Brazil
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines

Prophylaxis of Avian Influenza Vaccine

United Kingdom
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Influenza

United States
Paolo Corradini
University of Milan

Completed

Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients

Lymphoma | Multiple Myeloma | Myeloproliferative Disease

Italy

3

Subscribe